Onconetix (NASDAQ:ONCO – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($76.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($45,050.00) by $44,973.99, FiscalAI reports. Onconetix had a negative return on equity of 91.95% and a negative net margin of 1,575.89%. The business had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.10 million.
Onconetix Stock Up 3.1%
Onconetix stock opened at $3.00 on Wednesday. Onconetix has a 12 month low of $2.76 and a 12 month high of $1,610.00. The stock’s 50 day moving average is $5.99 and its 200-day moving average is $102.80.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on the stock. Weiss Ratings downgraded shares of Onconetix from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday. Wall Street Zen upgraded shares of Onconetix from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock presently has an average rating of “Sell”.
View Our Latest Stock Report on ONCO
Onconetix Company Profile
Onconetix, Inc. is a biotechnology company focused on cancer-related diagnostics and therapeutics, with an emphasis on prostate health. Its portfolio includes Proclarix, a blood-based diagnostic test developed to help assess prostate cancer risk. Proclarix was developed by Swiss company Proteomedix, which Onconetix acquired in 2023. The test has received a CE mark for use in Europe; its availability and regulatory status may differ in other markets. Onconetix was formerly known as Blue Water Biotech before adopting its current name in 2024.
Read More
- Five stocks we like better than Onconetix
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
